<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK316514" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK316514/" /><meta name="ncbi_pagename" content="Primary Hyperoxaluria Type 3 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Primary Hyperoxaluria Type 3 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Primary Hyperoxaluria Type 3" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/09/24" /><meta name="citation_author" content="Dawn S Milliner" /><meta name="citation_author" content="Peter C Harris" /><meta name="citation_author" content="John C Lieske" /><meta name="citation_pmid" content="26401545" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK316514/" /><meta name="citation_keywords" content="Primary Hyperoxaluria Type III" /><meta name="citation_keywords" content="Probable 4-hydroxy-2-oxoglutarate aldolase, mitochondrial" /><meta name="citation_keywords" content="HOGA1" /><meta name="citation_keywords" content="Primary Hyperoxaluria Type 3" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Primary Hyperoxaluria Type 3" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Dawn S Milliner" /><meta name="DC.Contributor" content="Peter C Harris" /><meta name="DC.Contributor" content="John C Lieske" /><meta name="DC.Date" content="2015/09/24" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK316514/" /><meta name="description" content="Primary hyperoxaluria type 3 (PH3) is characterized by recurring calcium oxalate stones beginning in childhood or adolescence and, on occasion, nephrocalcinosis or reduced kidney function. In 50%-65% of individuals with PH3 stone formation begins prior to age five years. Although the frequency and severity of stone activity often seem to abate by adolescence and adulthood, stone formation can occur throughout life and some adults have many stones. To date systemic oxalosis has not been reported in PH3." /><meta name="og:title" content="Primary Hyperoxaluria Type 3" /><meta name="og:type" content="book" /><meta name="og:description" content="Primary hyperoxaluria type 3 (PH3) is characterized by recurring calcium oxalate stones beginning in childhood or adolescence and, on occasion, nephrocalcinosis or reduced kidney function. In 50%-65% of individuals with PH3 stone formation begins prior to age five years. Although the frequency and severity of stone activity often seem to abate by adolescence and adulthood, stone formation can occur throughout life and some adults have many stones. To date systemic oxalosis has not been reported in PH3." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK316514/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ph3/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK316514/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8DEB54E0420AC100000000044001BD.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK316514_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK316514_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ph2/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/trimethylaminuria/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK316514_"><span class="title" itemprop="name">Primary Hyperoxaluria Type 3</span></h1><p class="contrib-group"><span itemprop="author">Dawn S Milliner</span>, MD, <span itemprop="author">Peter C Harris</span>, PhD, and <span itemprop="author">John C Lieske</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK316514_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK316514_ai__"><div class="contrib half_rhythm"><span itemprop="author">Dawn S Milliner</span>, MD<div class="affiliation small">Mayo Clinic<br />Rochester, Minnesota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.oyam@nwad.renillim" class="oemail">ude.oyam@nwad.renillim</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Peter C Harris</span>, PhD<div class="affiliation small">Mayo Clinic<br />Rochester, Minnesota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.oyam@retep.sirrah" class="oemail">ude.oyam@retep.sirrah</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">John C Lieske</span>, MD<div class="affiliation small">Mayo Clinic<br />Rochester, Minnesota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.oyam@nhoj.ekseil" class="oemail">ude.oyam@nhoj.ekseil</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 24, 2015</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ph3.Summary" itemprop="description"><h2 id="_ph3_Summary_">Summary</h2><div><h4 class="inline">Clinical description.</h4><p>Primary hyperoxaluria type 3 (PH3) is characterized by recurring calcium oxalate stones beginning in childhood or adolescence and, on occasion, nephrocalcinosis or reduced kidney function. In 50%-65% of individuals with PH3 stone formation begins prior to age five years. Although the frequency and severity of stone activity often seem to abate by adolescence and adulthood, stone formation can occur throughout life and some adults have many stones. To date systemic oxalosis has not been reported in PH3.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of PH3 is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with calcium oxalate kidney stone(s) and/or nephrocalcinosis, urine oxalate &#x0003e;0.7 mmol/1.73 m<sup>2</sup>/24 hours (in those with preserved kidney function), increased concentration of plasma oxalate (particularly in those with reduced kidney function), and <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>) pathogenic variants in <i>HOGA1</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations</i>: Reduction of urine supersaturation of calcium oxalate by maintaining high oral fluid intake at all times and use of an inhibitor of calcium oxalate crystallization such as potassium or sodium citrate; prevention of stone complications by prompt relief of urinary tract obstruction and treatment of urinary tract infections; and avoidance of marked dietary oxalate excess.</p><p><i>Prevention of primary manifestations:</i> Same as <i>Treatment of manifestations.</i></p><p><i>Surveillance:</i> For those who are stable, annual clinical assessment of: stone-related symptoms (pain), frequency of passage of urinary stones and/or gravel, urinary tract infection; adherence to high fluid intake and medication schedule; annual: assessment of kidney function by serum creatinine, measurement of plasma oxalate concentration in those with impaired renal function, 24-hour urine oxalate and supersaturation study, and renal ultrasound examination or other imaging to monitor for stone formation.</p><p><i>Agents/circumstances to avoid:</i> Intravascular volume contraction, delays in treatment of acute stone episodes, marked dietary oxalate excess, high-dose ascorbic acid, and nephrotoxic agents.</p><p><i>Evaluation of relatives at risk:</i> Presymptomatic diagnosis and treatment is warranted in relatives at risk to reduce stone formation and the risk of nephrocalcinosis and chronic kidney disease.</p><p><i>Pregnancy management:</i> Adequate fluid intake throughout the pregnancy.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>PH3 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <i>HOGA1</i> pathogenic variants in the family are known<i>.</i></p></div></div><div id="ph3.Diagnosis"><h2 id="_ph3_Diagnosis_">Diagnosis</h2><div id="ph3.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Primary hyperoxaluria type 3 (PH3) should be considered in any individual with the following:</p><ul><li class="half_rhythm"><div>Recurring calcium oxalate stones</div></li><li class="half_rhythm"><div>Onset of stone disease in childhood or adolescence</div></li><li class="half_rhythm"><div>Nephrocalcinosis</div></li><li class="half_rhythm"><div>Reduced kidney function in the presence of calcium stones or nephrocalcinosis</div></li><li class="half_rhythm"><div>Family history of chronic kidney disease and/or recurring calcium oxalate stones consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance</div></li></ul><p>Note: Since <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> stone disease is very common [<a class="bk_pop" href="#ph3.REF.worcester.2010.954">Worcester &#x00026; Coe 2010</a>] and since calcium oxalate is found in approximately 80% of stones [<a class="bk_pop" href="#ph3.REF.worcester.2010.954">Worcester &#x00026; Coe 2010</a>], a high index of clinical suspicion is necessary to identify the small proportion of individuals who form calcium oxalate stones as a result of PH3.</p></div><div id="ph3.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>Algorithms for the diagnosis of the primary hyperoxalurias have recently been published [<a class="bk_pop" href="#ph3.REF.harambat.2011.864580">Harambat et al 2011</a>, <a class="bk_pop" href="#ph3.REF.edvardsson.2013.1923">Edvardsson et al 2013</a>] (see <a class="figpopup" href="/books/NBK316514/figure/ph3.F1/?report=objectonly" target="object" rid-figpopup="figph3F1" rid-ob="figobph3F1">Figure 1</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figph3F1" co-legend-rid="figlgndph3F1"><a href="/books/NBK316514/figure/ph3.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figph3F1" rid-ob="figobph3F1"><img class="small-thumb" src="/books/NBK316514/bin/ph3-Image001.gif" src-large="/books/NBK316514/bin/ph3-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndph3F1"><h4 id="ph3.F1"><a href="/books/NBK316514/figure/ph3.F1/?report=objectonly" target="object" rid-ob="figobph3F1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Algorithm for the diagnostic evaluation of primary hyperoxaluria in an affected individual 1. Chronic kidney disease is defined as a glomerular filtration rate &#x0003c;50 mL/min/1.73 m<sup>2</sup>, or serum creatinine &#x02265;2x normal for age.</p></div></div><p>The diagnosis of PH3 is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the clinical findings of calcium oxalate kidney stone(s) and/or (on occasion) nephrocalcinosis and the following <b>biochemical</b> and <b>molecular genetic</b> findings.</p><div id="ph3.Biochemical_Findings"><h4>Biochemical Findings</h4><p><b>Urine oxalate.</b> &#x0003e;0.7 mmol/1.73 m<sup>2</sup>/24 hours in individuals with preserved kidney function (GFR &#x0003e;40 mL/min/1.7m<sup>2</sup>)</p><p>Note: (1) Urine oxalate may be lower in individuals with advanced chronic kidney disease (CKD). (2) In children the oxalate excretion rate must be corrected for 1.73 m<sup>2</sup> body surface area (BSA). (3) Urine oxalate should preferably be measured in a 24-hour urine sample; however, when timed urine collections cannot be obtained, a random urine oxalate/creatinine ratio can be used. Since normal ranges for oxalate/creatinine vary during childhood by age, age-related normal values should be consulted for accurate interpretation (see <a class="figpopup" href="/books/NBK316514/table/ph3.T.random_urine_oxalatetocreatinine_o/?report=objectonly" target="object" rid-figpopup="figph3Trandomurineoxalatetocreatinineo" rid-ob="figobph3Trandomurineoxalatetocreatinineo">Table 1</a>).</p><p><b>Plasma oxalate.</b> &#x0003e;20 &#x000b5;mol/L and/or systemic oxalosis in individuals with chronic kidney disease stages 3b, 4, and 5 (GFR &#x0003c;45 mL/min/1.73m<sup>2</sup>)</p><p><b>Urine glycolate, L-glycerate, 4-hydroxyoxoglutarate (HOG),</b> and <b>dihydroxyglutarate (DHG)</b></p><ul><li class="half_rhythm"><div>Increased urine glycolate in the presence of hyperoxaluria is suggestive, but not diagnostic of PH1.</div></li><li class="half_rhythm"><div>Increased urine L-glycerate in an individual with hyperoxaluria suggests PH2 (see <a href="#ph3.Differential_Diagnosis">Differential Diagnosis</a>).</div></li><li class="half_rhythm"><div>Increased HOG and DHG suggest PH3 (see <a href="#ph3.Differential_Diagnosis">Differential Diagnosis</a>).</div></li></ul><p>Note: The patient should not be receiving pyridoxine or vitamin supplements when urine and plasma oxalate and urine glycolate measurements are being obtained for the purpose of diagnosis.</p><div id="ph3.T.random_urine_oxalatetocreatinine_o" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Random Urine Oxalate-to-Creatinine (Ox/Cr) Ratio by Age</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK316514/table/ph3.T.random_urine_oxalatetocreatinine_o/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ph3.T.random_urine_oxalatetocreatinine_o_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age</th><th id="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Upper Limit of Normal (mmol/mmol)&#x000a0;<sup>2</sup></th><th id="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(mg/mg)</th></tr></thead><tbody><tr><td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x0003c;6 months&#x000a0;<sup>1</sup></td><td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.37</td><td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.29</td></tr><tr><td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 months to 2 years</td><td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.26</td><td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.20</td></tr><tr><td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x0003e;2 years to 5 years</td><td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.14</td><td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.11</td></tr><tr><td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 to 12 years</td><td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.08</td><td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.06</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Based on: <a class="bk_pop" href="#ph3.REF.gibbs.1969.901">Gibbs &#x00026; Watts [1969]</a>, <a class="bk_pop" href="#ph3.REF.barratt.1991.501">Barratt et al [1991]</a>, <a class="bk_pop" href="#ph3.REF.morgenstern.1993.248">Morgenstern et al [1993]</a>, <a class="bk_pop" href="#ph3.REF.von_schnakenburg.1994.27">von Schnakenburg et al [1994]</a></p></div></dd><dt>1. </dt><dd><div id="ph3.TF.1.1"><p class="no_margin">Urine Ox/Cr ratios are higher in very premature infants than in term infants, especially when they are receiving parenteral nutrition containing amino acids. The ratio falls when premature infants are receiving only glucose and electrolyte solutions [<a class="bk_pop" href="#ph3.REF.campfield.1989.860">Campfield &#x00026; Braden 1989</a>].</p></div></dd><dt>2. </dt><dd><div id="ph3.TF.1.2"><p class="no_margin">When very high dietary oxalate or low dietary calcium is suspected as the cause of the hyperoxaluria, the diet should be corrected and the urine oxalate remeasured for verification.</p></div></dd></dl></div></div></div></div><div id="ph3.Molecular_Genetic_Findings"><h4>Molecular Genetic Findings</h4><p>Diagnostic findings are <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>) pathogenic variants in <i>HOGA1</i> [<a class="bk_pop" href="#ph3.REF.belostotsky.2012.1497">Belostotsky et al 2012</a>] (see <a class="figpopup" href="/books/NBK316514/table/ph3.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figph3Tmoleculargenetictestingusedin" rid-ob="figobph3Tmoleculargenetictestingusedin">Table 2</a>).</p><p>Molecular testing approaches can include <b>a</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p><b>Multigene panel.</b> Because of the overlapping phenotypes of the three types of primary hyperoxaluria (see <a href="#ph3.Differential_Diagnosis">Differential Diagnosis</a>), the authors recommend sequencing the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <i>AGXT</i> (PH1), <i>GRHPR</i> (PH2), and <i>HOGA1</i> (PH3) [<a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>, <a class="bk_pop" href="#ph3.REF.williams.2015.69">Williams et al 2015</a>].</p><p>If only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is detected in one of these three genes in an individual whose clinical and laboratory findings strongly suggest PH, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> should be performed [<a class="bk_pop" href="#ph3.REF.nogueira.2000.384">Nogueira et al 2000</a>, <a class="bk_pop" href="#ph3.REF.monico.2007.1905">Monico et al 2007</a>]. The finding of only a single pathogenic variant should not be considered diagnostic without additional biochemical evidence (e.g., elevated HOG and DHG).</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing,</b> which may be used if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is detected on a panel of the three PH-related genes, includes a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> for a wide range of kidney stone-associated diseases [<a class="bk_pop" href="#ph3.REF.halbritter.2015.543">Halbritter et al 2015</a>] and <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="ph3.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Primary Hyperoxaluria Type 3</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK316514/table/ph3.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ph3.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ph3.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ph3.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_ph3.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_ph3.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>HOGA1</i></td><td headers="hd_h_ph3.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>2</sup></td><td headers="hd_h_ph3.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All pathogenic variants reported to date&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_ph3.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></td><td headers="hd_h_ph3.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown (i.e., no data on <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted del/dup analysis are available)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ph3.TF.2.1"><p class="no_margin">See <a href="/books/NBK316514/#ph3.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein. See <a href="#ph3.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>2. </dt><dd><div id="ph3.TF.2.2"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>3. </dt><dd><div id="ph3.TF.2.3"><p class="no_margin"><a class="bk_pop" href="#ph3.REF.belostotsky.2010">Belostotsky et al [2010]</a>, <a class="bk_pop" href="#ph3.REF.williams.2012.3191">Williams et al [2012]</a>, <a class="bk_pop" href="#ph3.REF.beck.2013.162">Beck et al [2013]</a>, <a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al [2015]</a></p></div></dd><dt>4. </dt><dd><div id="ph3.TF.2.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div></div></div></div><div id="ph3.Clinical_Characteristics"><h2 id="_ph3_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ph3.Clinical_Description"><h3>Clinical Description</h3><p>Individuals with primary hyperoxaluria type 3 (PH3) most often present in childhood with signs or symptoms related to kidney stones including hematuria, frequent urination, dysuria, blood visible in the urine, or pain associated with a stone.</p><p>Although the stones are likely to be discovered due to symptoms, they may be detected incidentally on imaging studies performed for other purposes.</p><p>Approximately 50%-65% of individuals with PH3 present with a stone prior to age five years [<a class="bk_pop" href="#ph3.REF.monico.2011.2289">Monico et al 2011</a>, <a class="bk_pop" href="#ph3.REF.matsumoto.2015">Matsumoto &#x00026; Milliner 2015</a>]. Although the frequency and severity of stone activity appear to abate in adolescence and adulthood [<a class="bk_pop" href="#ph3.REF.hoppe.2012.3024">Hoppe 2012</a>], stone formation can occur throughout life, and some adults have many stones.</p><p>Nephrocalcinosis has been reported to date only occasionally in individuals with PH3 [<a class="bk_pop" href="#ph3.REF.williams.2012.3191">Williams et al 2012</a>, <a class="bk_pop" href="#ph3.REF.tang.2015.623">Tang et al 2015</a>].</p><p>Over time, kidney function may become compromised from frequent stones and/or nephrocalcinosis, resulting in chronic kidney disease (CKD). However, kidney function appears to remain better preserved among individuals with PH3 compared to those with PH1 or PH2 [<a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>].</p><p>To date, only one individual with PH3 has been reported to progress to end-stage renal disease. In this eight-year-old patient, stone removal procedures and urinary tract obstruction may have contributed to the loss of kidney function [<a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>].</p><p><b>Systemic oxalosis.</b> The plasma concentration of oxalate increases significantly in individuals with PH and advanced CKD. When the plasma oxalate concentration reaches super-saturation, calcium oxalate crystals are deposited in many body tissues. Crystal-induced injury can include cutaneous ulcers, vascular disease, cardiomyopathy, cardiac conduction disturbances, non-healing fractures, erythropoietin-resistant anemia, and retinal deposits [<a class="bk_pop" href="#ph3.REF.hoppe.2012.3024">Hoppe 2012</a>]. Although systemic oxalosis is well recognized in <a href="/books/n/gene/ph1/">PH1</a> and seen occasionally in <a href="/books/n/gene/ph2/">PH2</a>, it has not been reported to date in PH3, an observation consistent with the infrequency of end-stage renal disease (ESRD) in PH3.</p><p><b>Heterozygotes.</b> Although some heterozygotes (carriers) have had elevations of urinary oxalate [<a class="bk_pop" href="#ph3.REF.monico.2011.2289">Monico et al 2011</a>], this may be coincidental as it is not seen in the majority. As more families are studied, additional information is expected to provide a better understanding of the risk to heterozygotes.</p></div><div id="ph3.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Although no differences in phenotypic manifestations were noted among individuals with the two most common <i>HOGA1</i> pathogenic variants [<a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>], the relatively recent discovery of mutation of <i>HOGA1</i> as the cause of PH3 and the rarity of PH3 (&#x0003c;100 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals described to date) have limited this type of analysis.</p><p>Families of <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> heritage with PH3 have developed hypercalciuria in addition to hyperoxaluria [<a class="bk_pop" href="#ph3.REF.monico.2011.2289">Monico et al 2011</a>, <a class="bk_pop" href="#ph3.REF.hoppe.2012.3024">Hoppe 2012</a>]; however, to date no specific <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation has been established [<a class="bk_pop" href="#ph3.REF.belostotsky.2010">Belostotsky et al 2010</a>].</p></div><div id="ph3.Prevalence"><h3>Prevalence</h3><p>Surveys of clinicians in central Europe led to estimates of the prevalence of primary hyperoxaluria (of all causes) of 1-3 per million population [<a class="bk_pop" href="#ph3.REF.hoppe.2009.1264">Hoppe et al 2009</a>].</p><p>Among individuals with primary hyperoxaluria approximately 70% have PH1, 10% have PH2, 10% have PH3, and 10% have no as-yet identified genetic cause [<a class="bk_pop" href="#ph3.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</a>, <a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>].</p><p>Registry data of the Rare Kidney Stone Consortium and OxalEurope suggest a prevalence of PH3 that is similar to PH2 and approximately one sixth that of PH1.</p><p>By contrast, estimates from publicly available population data (NHLBI ESP) showed a PH3 <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of 1:185 [<a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>], which was similar to the rate observed for PH1, suggesting certain individuals with PH3 either remain undiagnosed or do not have clinical manifestations. Prevalence of PH3 from the <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> data is currently estimated at 1:136,000 [<a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>].</p><p>PH3 has been observed more commonly among individuals of <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> descent [<a class="bk_pop" href="#ph3.REF.belostotsky.2010">Belostotsky et al 2010</a>]; however, the true prevalence in this population is unknown.</p></div></div><div id="ph3.Genetically_Related_Allelic_Disorder"><h2 id="_ph3_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are currently known to be associated with pathogenic variants in <i>HOGA1</i>.</p></div><div id="ph3.Differential_Diagnosis"><h2 id="_ph3_Differential_Diagnosis_">Differential Diagnosis</h2><p>Any condition that causes calcium oxalate kidney stone disease or nephrocalcinosis and is associated with hyperoxaluria should be included in the differential diagnosis of primary hyperoxaluria type 3 (PH3).</p><div id="ph3.Primary_Hyperoxalurias"><h3>Primary Hyperoxalurias</h3><p>The three known types of primary hyperoxaluria (PH) are <a href="/books/n/gene/ph1/">PH1</a> (due to mutation of <i>AGXT</i>), <a href="/books/n/gene/ph2/">PH2</a> (mutation of <i>GRHPR</i>), and PH3 (mutation of <i>HOGA1</i>). Each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encodes an enzyme for different metabolic pathways relevant for the metabolism of glyoxylate [<a class="bk_pop" href="#ph3.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</a>]. Oxalate accumulates as an end product in all forms of PH; however, the specific pathways that lead to its accumulation in PH3 require further clarification [<a class="bk_pop" href="#ph3.REF.monico.2011.2289">Monico et al 2011</a>, <a class="bk_pop" href="#ph3.REF.riedel.2012.1544">Riedel et al 2012</a>, <a class="bk_pop" href="#ph3.REF.williams.2012.3191">Williams et al 2012</a>].</p><p>Of the primary hyperoxalurias, approximately 70% are PH1, 10% are PH2, 10% PH3, and 10% do not have an identified genetic cause [<a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>]. The clinical manifestations of the three known types of PH overlap considerably.</p><p>In some individuals with PH3, significant stone manifestations have been observed in infancy and early childhood; these appear to have abated by later childhood or adolescence [<a class="bk_pop" href="#ph3.REF.hoppe.2012.3024">Hoppe 2012</a>, <a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>].</p><p>Urine oxalate excretion rates tend to be lower in individuals with PH3 than in those with PH1 or PH2 [<a class="bk_pop" href="#ph3.REF.monico.2011.2289">Monico et al 2011</a>, <a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>]. In PH3 urine oxalate excretion appears to be more variable over time. However, because of the overlap of urinary oxalate excretion in all three types, the type of PH (and thus the diagnosis of PH3) cannot be confirmed on this basis alone [<a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>].</p><p>Hypercalciuria, observed in a subset of individuals with PH3, is not usually observed in PH1 and PH2 [<a class="bk_pop" href="#ph3.REF.monico.2011.2289">Monico et al 2011</a>, <a class="bk_pop" href="#ph3.REF.williams.2012.3191">Williams et al 2012</a>].</p><p>Hyperoxaluria of the degree observed in individuals with primary hyperoxaluria causes deposition of calcium oxalate crystals in the kidney (nephrocalcinosis) associated with inflammation, kidney damage, and often chronic kidney disease and/or end-stage renal disease (ESRD). ESRD appears to be unusual in PH3, having been reported in just one individual to date [<a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>]; however, modest renal impairment has been described in other cohorts [<a class="bk_pop" href="#ph3.REF.allard.2015.1807">Allard et al 2015</a>].</p><p>Systemic calcium oxalate deposition (systemic oxalosis) may develop due to high levels of plasma oxalate in patients with PH who have advanced CKD. Systemic oxalosis results in varying degrees of organ dysfunction including infiltrative cardiomyopathy, arrhythmias due to involvement of the cardiac conduction system, erythropoietin-resistant anemia due to extensive crystal deposition in the bone marrow, pathologic fractures, and/or retinal oxalate deposition [<a class="bk_pop" href="#ph3.REF.hoppe.2009.1264">Hoppe et al 2009</a>]. Systemic oxalosis has not yet been reported in any individual with PH3, an observation consistent with the infrequency of end-stage renal disease (ESRD) in PH3.</p><p>Differences in urinary metabolites other than oxalate can provide clues regarding the most likely type of PH.</p><ul><li class="half_rhythm"><div><b>4-hydroxy-2-oxoglutarate (HOG).</b> In PH3 urinary levels of HOG are often high, whereas in PH1 and PH2 urinary HOG is undetectable [<a class="bk_pop" href="#ph3.REF.riedel.2012.1544">Riedel et al 2012</a>]. The diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> and specificity of this finding remain to be determined [<a class="bk_pop" href="#ph3.REF.belostotsky.2012.1497">Belostotsky et al 2012</a>, <a class="bk_pop" href="#ph3.REF.riedel.2012.1544">Riedel et al 2012</a>].</div></li><li class="half_rhythm"><div><b>Urinary glycolate</b> may be elevated in PH1 or occasionally in PH3 [<a class="bk_pop" href="#ph3.REF.williams.2012.3191">Williams et al 2012</a>].</div></li><li class="half_rhythm"><div><b>Urine glycerate</b> is increased in most individuals with PH2; however, exceptions (perhaps related to the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing process) occur [<a class="bk_pop" href="#ph3.REF.rumsby.2001.1697">Rumsby et al 2001</a>].</div></li></ul><p>See <a href="http://www.omim.org/phenotypicSeries/PS259900" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Primary hyperoxaluria: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p><p><b>Idiopathic calcium oxalate stone disease</b> can be associated with mild hyperoxaluria. The hyperoxaluria is typically of a lesser degree (&#x0003c;0.6 mmol/day) than that observed in the primary hyperoxalurias, is variable from one collection to the next, and is frequently associated with mild hypercalciuria.</p></div><div id="ph3.Secondary_Hyperoxalurias"><h3>Secondary Hyperoxalurias</h3><p>Secondary forms of hyperoxaluria are not uncommon and should be systematically considered.</p><p><b>Dietary or other sources of excessive oxalate or oxalate precursors</b> should be considered in the differential diagnosis. Very high doses of vitamin C are a potential cause. Exposure to toxins such as ethylene glycol can cause marked hyperoxaluria and associated acute renal failure.</p><p><b>Enteric hyperoxaluria</b> results from any cause of fat malabsorption in the small intestine. In the colon, this undigested fat combines with calcium and decreases the amount of calcium available to bind to oxalate. This free oxalate is absorbed. In addition, fatty acids that are not absorbed in the small intestine can damage the colonic mucosa, leading to further increase in oxalate absorption. Thus, any gastrointestinal disease or surgery that impairs fat absorption is a potential cause of enteric hyperoxaluria [<a class="bk_pop" href="#ph3.REF.kumar.2011.654">Kumar et al 2011</a>]. Hyperoxaluria resulting from short bowel syndrome and following malabsorptive types of gastric bypass surgery can be quite marked, overlapping the range seen in inherited PH of all types.</p><p>Medications that interfere with fat absorption from the GI tract (e.g., orlistat) can be associated with hyperoxaluria.</p><p>Marked deficiency of dietary calcium, leaving a greater proportion of oxalate free in the intestinal lumen, can result in increased absorption of oxalate resulting in hyperoxaluria.</p><p><b>Nephrocalcinosis of prematurity</b> occurs in a significant proportion of infants born prior to 28 weeks' gestation and is characterized by both nephrocalcinosis and nephrolithiasis [<a class="bk_pop" href="#ph3.REF.habbig.2011.1278">Habbig et al 2011</a>]. Risk factors among premature infants thought to contribute to this disease include urine oxalate that is higher than that observed in infants born at term [<a class="bk_pop" href="#ph3.REF.schellfeith.2010.221">Schell-Feith et al 2010</a>] as well as hypercalciuria and hypocitric aciduria. Calcium oxalate crystals have been detected in the renal parenchyma [<a class="bk_pop" href="#ph3.REF.schellfeith.2010.221">Schell-Feith et al 2010</a>]. Since individuals with PH3 can develop stones in infancy or during early childhood [<a class="bk_pop" href="#ph3.REF.hoppe.2012.3024">Hoppe 2012</a>, <a class="bk_pop" href="#ph3.REF.matsumoto.2015">Matsumoto &#x00026; Milliner 2015</a>], there may be confusion with stones or nephrocalcinosis related to prematurity.</p></div></div><div id="ph3.Management"><h2 id="_ph3_Management_">Management</h2><div id="ph3.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with primary hyperoxaluria type 3 (PH3), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Kidney imaging for assessment of number and location of stones and presence of nephrocalcinosis</div></li><li class="half_rhythm"><div>Measurement of plasma oxalate concentration to assess the degree of oxalate overproduction</div></li><li class="half_rhythm"><div>Baseline 24-hour collection with measurement of oxalate, calcium, citrate, pH, urine volume, and other components of a supersaturation profile to identify specific risk factors for stones &#x02013; information that is valuable in guiding treatment</div></li><li class="half_rhythm"><div>Assessment of kidney function by serum creatinine and eGFR</div></li><li class="half_rhythm"><div>If chronic kidney disease (CKD) is present, evaluation for signs of systemic oxalosis by physical examination (livedo reticularis or non-healing ulcers of the skin), echocardiography (oxalate cardiomyopathy), electrocardiogram (conduction disturbances), complete blood count (erythropoietin-resistant anemia), bone films (sclerosis, pathologic fractures due to oxalate osteodystrophy), and retinal examination (retinal oxalate deposits)</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="ph3.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Reduction of urine supersaturation of calcium oxalate</b> in order to reduce stone formation and formation of calcium oxalate crystals that can be injurious to the kidney:</p><ul><li class="half_rhythm"><div>Maintainance of high oral fluid intake (&#x0003e;2.5 L/m<sup>2</sup> BSA)</div></li><li class="half_rhythm"><div>Oral administration of an inhibitor of calcium oxalate crystallization. Most patients are treated with one of these agents, which include potassium and sodium citrate [<a class="bk_pop" href="#ph3.REF.leumann.2001.1986">Leumann &#x00026; Hoppe 2001</a>], orthophosphate [<a class="bk_pop" href="#ph3.REF.milliner.1994.1553">Milliner et al 1994</a>], or magnesium [<a class="bk_pop" href="#ph3.REF.watts.1994.593">Watts 1994</a>]. Note: Simultaneous administration of citrate and phosphate should be done with caution due to the potential for increasing calcium phosphate supersaturation.</div></li></ul><p><b>Avoidance of supersaturation of calcium oxalate in the blood.</b> Although there is little experience with chronic kidney disease in PH3, a decline in GFR to less than approximately 40 mL/min/1.73m<sup>2</sup> would be expected to result in increased plasma oxalate and the potential for systemic oxalosis (as in other forms of PH). If plasma oxalate exceeds 35-50 &#x003bc;mol/L dialysis or transplantation is needed to reduce the risk of multiorgan complications of calcium oxalate deposition.</p><p><b>Prevention of stone complications</b> through regular monitoring (see <a href="#ph3.Surveillance">Surveillance</a>) and prompt attention to the following, any of which can damage kidney function:</p><ul><li class="half_rhythm"><div>Alleviate obstruction of the urinary tract by a stone promptly through stent placement and/or stone removal.</div></li><li class="half_rhythm"><div>Maintain continuous fluid intake and urine flow before, during, and for several days after stone removal procedures.</div></li><li class="half_rhythm"><div>Treat urinary tract infections promptly and thoroughly, as bacteria may cause pyelonephritis or infect stones and complicate management.</div></li></ul><p><b>Avoidance of acute kidney injury</b> by avoiding intravascular volume contraction at all times. This may necessitate intravenous fluids during severe gastroenteritis or other circumstances in which oral fluid intake cannot be maintained.</p><p><b>Avoidance of marked dietary oxalate excess.</b> Since the source of the excess oxalate in PH3 is metabolic overproduction, little is gained by strict low-oxalate diets, which in young children may compromise nutrition. Simple avoidance of marked dietary oxalate excess is recommended.</p></div><div id="ph3.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>See <a href="#ph3.Treatment_of_Manifestations">Treatment of Manifestations</a>.</p></div><div id="ph3.Surveillance"><h3>Surveillance</h3><p>Attention to ongoing care, including adherence to high fluid intake and medication schedule, is essential to good outcomes.</p><p>For patients who are stable and doing well (see Note) the following are recommended annually:</p><ul><li class="half_rhythm"><div>Clinical assessment of stone-related symptoms including pain, frequency of passage of stones or gravel in the urine, and urinary tract infection</div></li><li class="half_rhythm"><div>Assessment of kidney function (serum creatinine and eGFR) and electrolytes</div></li><li class="half_rhythm"><div>Measurement of plasma oxalate concentration, particularly in those with any impairment of glomerular filtration rate (GFR)</div></li><li class="half_rhythm"><div>24-hour urine oxalate and supersaturation study. During follow up, changes in the urine supersaturation can be used to monitor the effectiveness of therapy by confirming that the crystallization potential has decreased.</div></li><li class="half_rhythm"><div>Renal ultrasound examination or other imaging to monitor for stone formation</div></li></ul><p>Note: Very young patients, those with complex stone problems, and those with reduced kidney function need closer management with more frequent assessments.</p></div><div id="ph3.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following should be avoided:</p><ul><li class="half_rhythm"><div>Intravascular volume contraction (Note: Liberal use of intravenous fluids is indicated whenever oral fluid intake is inadequate.)</div></li><li class="half_rhythm"><div>Delays in treatment of acute stone episodes</div></li><li class="half_rhythm"><div>Nephrotoxic agents</div></li><li class="half_rhythm"><div>Marked dietary oxalate excess</div></li><li class="half_rhythm"><div>High-dose ascorbic acid</div></li></ul></div><div id="ph3.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Using <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <i>HOGA1</i> pathogenic variants found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, it is appropriate to evaluate the older and younger sibs of a proband in order to identify as early as possible those who would benefit from early treatment and preventive measures.</p><ul><li class="half_rhythm"><div>Urine oxalate should be measured in all sibs who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> (i.e., have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>HOGA1</i> pathogenic variants) or who are carriers (i.e., <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for one <i>HOGA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>)</div></li><li class="half_rhythm"><div>Any sib with elevated urine oxalate/creatinine ratio or elevated oxalate excretion rate corrected for 1.73 m<sup>2</sup> BSA should undergo kidney ultrasound examination, measurement of plasma oxalate concentration, a baseline 24-hour urine collection with a supersaturation profile, and measurement of serum creatinine concentration (see <a href="#ph3.Evaluations_Following_Initial_Diagno">Evaluations Following Initial Diagnosis</a>).</div></li></ul><p>See <a href="#ph3.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ph3.Pregnancy_Management"><h3>Pregnancy Management</h3><p>There have been no studies of pregnancy in women with PH3. However, most women with PH1 or PH2 who had good kidney function during pregnancy have done well and have delivered healthy infants [<a class="bk_pop" href="#ph3.REF.norby.2004.277">Norby &#x00026; Milliner 2004</a>].</p><p>Adequate fluid intake should be maintained throughout the pregnancy. Circumstances that compromise fluid intake, such as hyperemesis gravidarum, should prompt early initiation of IV fluid to maintain adequate hydration.</p><p>Stones that become symptomatic during pregnancy may require routine (but specialized) techniques for management.</p><p>In patients with stones, urinary tract infections should be treated promptly and thoroughly due to the potential for bacteria to cause pyelonephritis or infect stones and complicate management.</p></div><div id="ph3.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Humans cannot degrade oxalate; however, certain bacteria use oxalate as an energy source. Preliminary studies suggest that oral administration of <i>O. formigenes</i> could reduce oxalate excretion in individuals with PH. Two previous double-blind studies were inconclusive [<a class="bk_pop" href="#ph3.REF.hoppe.2006.1305">Hoppe et al 2006</a>]. A third clinical trial is under way in Europe, with results expected in 2015.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="ph3.Genetic_Counseling"><h2 id="_ph3_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ph3.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Primary hyperoxaluria type 3 (PH3) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="ph3.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (i.e., carriers of one <i>HOGA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are usually asymptomatic; however, exceptions may occur (see <a href="#ph3.Clinical_Description">Clinical Description</a>, Heterozygotes).</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are usually asymptomatic; however, exceptions may occur (see <a href="#ph3.Clinical_Description">Clinical Description</a>, Heterozygotes).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with PH3 are obligate heterozygotes (carriers) for a <i>HOGA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (i.e., <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>) for a <i>HOGA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="ph3.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>HOGA1</i> pathogenic variants in the family<i>.</i></p></div><div id="ph3.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#ph3.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ph3.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>HOGA1</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>While there is interest in prenatal testing in PH, especially in families with early renal failure, the interest in prenatal testing for PH3 is low given that the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is usually relatively mild and renal failure is rare. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="ph3.Resources"><h2 id="_ph3_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=hyperoxaluriaprimary" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Primary hyperoxaluria</a></div></li><li class="half_rhythm"><div><b>Oxalosis &#x00026; Hyperoxaluria Foundation (OHF)</b></div><div>201 East 19th Street</div><div>Suite 12E</div><div>New York NY 10003</div><div><b>Phone:</b> 800-643-8699 (toll-free)</div><div><b>Email:</b> info@ohf.org</div><div><a href="http://www.ohf.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ohf.org</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li><li class="half_rhythm"><div><b>Rare Kidney Stone Consortium Registry</b></div><div><b>Phone:</b> 800-270-4637 (toll-free)</div><div><b>Email:</b> hyperoxaluriacenter@mayo.edu</div><div><a href="http://www.mayo.edu/research/departments-divisions/department-internal-medicine/division-nephrology-hypertension/rare-kidney-stone-consortium-registry/rare-kidney-stone-consortium-registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Rare Kidney Stone Consortium Registry</a></div></li></ul></div><div id="ph3.Molecular_Genetics"><h2 id="_ph3_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ph3.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Primary Hyperoxaluria Type 3: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK316514/table/ph3.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ph3.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ph3.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ph3.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ph3.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ph3.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ph3.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ph3.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ph3.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/112817" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>HOGA1</i></a></td><td headers="hd_b_ph3.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=112817" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">10q24<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_ph3.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q86XE5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Probable 4-hydroxy-2-oxoglutarate aldolase, mitochondrial</a></td><td headers="hd_b_ph3.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/HOGA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HOGA1 database</a><br /><a href="https://www.uclh.nhs.uk/OurServices/ServiceA-Z/PATH/PATHBIOMED/CBIO/Pages/Phmdatabase.aspx" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Primary hyperoxaluria mutation database</a></td><td headers="hd_b_ph3.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=HOGA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HOGA1</a></td><td headers="hd_b_ph3.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=HOGA1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HOGA1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ph3.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ph3.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Primary Hyperoxaluria Type 3 (<a href="/omim/613597,613616" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK316514/table/ph3.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ph3.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613597" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613597</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4-@HYDROXY-2-OXOGLUTARATE ALDOLASE 1; HOGA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613616" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613616</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HYPEROXALURIA, PRIMARY, TYPE III; HP3</td></tr></tbody></table></div></div><p><b>Gene structure.</b> The longest <i>HOGA1</i> transcript variant (<a href="/nuccore/NM_138413.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_138413.3</a>) has a <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> of 981 bp encoded by seven exons. The <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> size of <i>HOGA1</i> is ~28.5 kb.</p><p><i>HOGA1</i> was previously termed <i>DHDPSL</i> [<a class="bk_pop" href="#ph3.REF.belostotsky.2010">Belostotsky et al 2010</a>, <a class="bk_pop" href="#ph3.REF.riedel.2011.e26021">Riedel et al 2011</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK316514/#ph3.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Approximately 40 different <i>HOGA1</i> pathogenic variants have been described [<a class="bk_pop" href="#ph3.REF.belostotsky.2010">Belostotsky et al 2010</a>, <a class="bk_pop" href="#ph3.REF.williams.2012.3191">Williams et al 2012</a>, <a class="bk_pop" href="#ph3.REF.beck.2013.162">Beck et al 2013</a>, <a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>]. (See <a href="/books/NBK316514/#ph3.molgen.TA">Table A</a> for <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> databases.) The vast majority of individuals with PH3 have two pathogenic non-truncating <i>HOGA1</i> variants [<a class="bk_pop" href="#ph3.REF.hopp.2015.2559">Hopp et al 2015</a>]; only one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual with two pathogenic truncating <i>HOGA1</i> variants has been described [<a class="bk_pop" href="#ph3.REF.williams.2012.3191">Williams et al 2012</a>]. It is not known if this observation is significant.</p><p>Two common pathogenic variants, an <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> and an atypical <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> event (<a class="figpopup" href="/books/NBK316514/table/ph3.T.hoga1_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figph3Thoga1pathogenicvariantsdiscusse" rid-ob="figobph3Thoga1pathogenicvariantsdiscusse">Table 3</a>), account for nearly 75% of all pathogenic variants.</p><ul><li class="half_rhythm"><div>The p.Glu315del <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is enriched in the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> population [<a class="bk_pop" href="#ph3.REF.belostotsky.2010">Belostotsky et al 2010</a>].</div></li><li class="half_rhythm"><div>The atypical <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> change, c.700+5G&#x0003e;T, results in an <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> of 51 bp [<a class="bk_pop" href="#ph3.REF.monico.2011.2289">Monico et al 2011</a>, <a class="bk_pop" href="#ph3.REF.williams.2012.3191">Williams et al 2012</a>].</div></li></ul><div id="ph3.T.hoga1_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>HOGA1</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK316514/table/ph3.T.hoga1_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ph3.T.hoga1_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.944_946delAGG&#x000a0;<sup>1</sup></td><td headers="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu315del</td><td headers="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_138413.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_138413<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_612422.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_612422<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.700+5G&#x0003e;T&#x000a0;<sup>2,&#x000a0;3</sup></td><td headers="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 2</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="ph3.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#ph3.REF.belostotsky.2010">Belostotsky et al [2010]</a></p></div></dd><dt>2. </dt><dd><div id="ph3.TF.3.2"><p class="no_margin">In silico analysis predicted use of another donor <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> 51 nucleotides downstream resulting in an <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> of 17 amino acids [<a class="bk_pop" href="#ph3.REF.belostotsky.2010">Belostotsky et al 2010</a>], subsequently confirmed in liver by <a class="bk_pop" href="#ph3.REF.williams.2012.3191">Williams et al [2012]</a> and by illegitimate transcription from Epstein Barr virus-transformed lymphocytes [<a class="bk_pop" href="#ph3.REF.monico.2011.2289">Monico et al 2011</a>].</p></div></dd><dt>3. </dt><dd><div id="ph3.TF.3.3"><p class="no_margin">Pathogenic variant originally (incorrectly) described as c.701+4G&#x0003e;T [<a class="bk_pop" href="#ph3.REF.belostotsky.2010">Belostotsky et al 2010</a>].</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> HOGA has 327 amino acids. Most of the protein (residues 38-321) has sequence homology with the TIM phosphate binding superfamily.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants are thought to result in loss of (or at least reduced) function of the protein.</p></div><div id="ph3.References"><h2 id="_ph3_References_">References</h2><div id="ph3.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.allard.2015.1807">Allard L, Cochat P, Leclerc AL, Cachat F, Fichtner C, De Souza VC, Garcia CD, Camoin-Schweitzer MC, Macher MA, Acquaviva-Bourdain C, Bacchetta J. Renal function can be impaired in children with primary hyperoxaluria type 3. <span><span class="ref-journal">Pediatr Nephrol. </span>2015;<span class="ref-vol">30</span>:1807–13.</span> [<a href="/pubmed/25972204" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25972204</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.barratt.1991.501">Barratt TM, Kasidas GP, Murdoch I, Rose GA. Urinary oxalate and glycolate excretion and plasma oxalate excretion. <span><span class="ref-journal">Arch Dis Child. </span>1991;<span class="ref-vol">66</span>:501–3.</span> [<a href="/pmc/articles/PMC1792981/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1792981</span></a>] [<a href="/pubmed/2031609" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2031609</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.beck.2013.162">Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, N&#x000fc;rnberg G, Yigit G, Salido EC, Hoppe B. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. <span><span class="ref-journal">Eur J Hum Genet. </span>2013;<span class="ref-vol">21</span>:162–72.</span> [<a href="/pmc/articles/PMC3548260/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3548260</span></a>] [<a href="/pubmed/22781098" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22781098</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.belostotsky.2012.1497">Belostotsky R, Pitt JJ, Frishberg Y. Primary hyperoxaluria type III--a model for studying perturbations in glyoxylate metabolism. <span><span class="ref-journal">J Mol Med. </span>2012;<span class="ref-vol">90</span>:1497–504.</span> [<a href="/pubmed/22729392" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22729392</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.belostotsky.2010">Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet. 2010;87-392-9. [<a href="/pmc/articles/PMC2933339/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2933339</span></a>] [<a href="/pubmed/20797690" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20797690</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.campfield.1989.860">Campfield T, Braden G. Urinary oxalate excretion by very low birth weight infants receiving parenteral nutrition. <span><span class="ref-journal">Pediatrics. </span>1989;<span class="ref-vol">84</span>:860–3.</span> [<a href="/pubmed/2508054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2508054</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.cochat.2013.649">Cochat P, Rumsby G. Primary hyperoxaluria. <span><span class="ref-journal">N Engl J Med. </span>2013;<span class="ref-vol">369</span>:649–58.</span> [<a href="/pubmed/23944302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23944302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.edvardsson.2013.1923">Edvardsson VO, Goldfarb DS, Lieske JC, Beara-Lasic L, Anglani F, Milliner DS, Palsson R. Hereditary causes of kidney stones and chronic kidney disease. <span><span class="ref-journal">Pediatr Nephrol. </span>2013;<span class="ref-vol">28</span>:1923–42.</span> [<a href="/pmc/articles/PMC4138059/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4138059</span></a>] [<a href="/pubmed/23334384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23334384</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.gibbs.1969.901">Gibbs DA, Watts RW. The variation of urinary oxalate excretion with age. <span><span class="ref-journal">J Lab Clin Med. </span>1969;<span class="ref-vol">73</span>:901–8.</span> [<a href="/pubmed/4891815" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4891815</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.habbig.2011.1278">Habbig S, Beck BB, Hoppe B. Nephrocalcinosis and urolithiasis in children. <span><span class="ref-journal">Kidney Int. </span>2011;<span class="ref-vol">80</span>:1278–91.</span> [<a href="/pubmed/21956187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21956187</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.halbritter.2015.543">Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, Fisher B, Spaneas L, Porath JD, Braun DA, Wassner AJ, Nelson CP, Tasic V, Sayer JA, Hildebrandt F. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. <span><span class="ref-journal">J Am Soc Nephrol. </span>2015;<span class="ref-vol">26</span>:543–51.</span> [<a href="/pmc/articles/PMC4341487/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4341487</span></a>] [<a href="/pubmed/25296721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25296721</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.harambat.2011.864580">Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Primary hyperoxaluria. <span><span class="ref-journal">Int J Nephrol. </span>2011;<span class="ref-vol">2011</span>:864580.</span> [<a href="/pmc/articles/PMC3124893/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3124893</span></a>] [<a href="/pubmed/21748001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21748001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.hopp.2015.2559">Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. <span><span class="ref-journal">J Am Soc Nephrol. </span>2015;<span class="ref-vol">26</span>:2559–70.</span> Milliner DS3, Harris PC, et al. [<a href="/pmc/articles/PMC4587693/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4587693</span></a>] [<a href="/pubmed/25644115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25644115</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.hoppe.2006.1305">Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. <span><span class="ref-journal">Kidney Int. </span>2006;<span class="ref-vol">70</span>:1305–11.</span> [<a href="/pubmed/16850020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16850020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.hoppe.2009.1264">Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. <span><span class="ref-journal">Kidney Int. </span>2009;<span class="ref-vol">75</span>:1264–71.</span> [<a href="/pmc/articles/PMC4577278/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4577278</span></a>] [<a href="/pubmed/19225556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19225556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.hoppe.2012.3024">Hoppe B. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type III. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2012;<span class="ref-vol">27</span>:3024–6.</span> [<a href="/pubmed/22851625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22851625</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.kumar.2011.654">Kumar R, Lieske JC, Collazo-Clavell ML, Sarr MG, Olson ER, Vrtiska TJ, Bergstralh EJ, Li X. Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. <span><span class="ref-journal">Surgery. </span>2011;<span class="ref-vol">149</span>:654–61.</span> [<a href="/pmc/articles/PMC3078956/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3078956</span></a>] [<a href="/pubmed/21295813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21295813</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.leumann.2001.1986">Leumann E., Hoppe B. The primary hyperoxalurias. <span><span class="ref-journal">J Am Soc Nephrol. </span>2001;<span class="ref-vol">12</span>:1986–93.</span> [<a href="/pubmed/11518794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11518794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.matsumoto.2015">Matsumoto J, Milliner DS. Primary hyperoxaluria. In: Coe F, Worcester E, Lingeman J, Evan A, eds. <em>Kidney Stones: A Multidisciplinary Approach to Diagnosis and Treatment</em>. Philadelphia, PA: Jaypee Brothers Medical Publications. In review 2015.</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.milliner.1994.1553">Milliner DS, Eickholt JT, Bergstralh EJ, Wilson DM, Smith LH. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. <span><span class="ref-journal">N Engl J Med. </span>1994;<span class="ref-vol">331</span>:1553–8.</span> [<a href="/pubmed/7969325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7969325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.monico.2011.2289">Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstralh EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2011;<span class="ref-vol">6</span>:2289–95.</span> [<a href="/pmc/articles/PMC3358997/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3358997</span></a>] [<a href="/pubmed/21896830" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21896830</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.monico.2007.1905">Monico CG, Rossetti S, Schwanz H, Olson J, Harris P, Milliner D. Comprehensive mutation screening in 55 type 1 primary hyperoxaluria probands shows feasibility of a gene-based diagnosis. <span><span class="ref-journal">J Am Soc Nephrol. </span>2007;<span class="ref-vol">18</span>:1905–14.</span> [<a href="/pubmed/17460142" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17460142</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.morgenstern.1993.248">Morgenstern BZ, Milliner DS, Murphy ME, Simmons PS, Moyer TP, Wilson DM, Smith LH. Urinary oxalate and glycolate excretion patterns in the first year of life: a longitudinal study. <span><span class="ref-journal">J Pediatr. </span>1993;<span class="ref-vol">123</span>:248–51.</span> [<a href="/pubmed/8345420" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8345420</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.nogueira.2000.384">Nogueira PK, Vuong TS, Bouton O, Maillard A, Marchand M, Rolland MO, Cochat P, Bozon D. Partial deletion of the AGXT gene (EX1_EX7del): a new genotype in hyperoxaluria type 1. <span><span class="ref-journal">Human Mutation. </span>2000;<span class="ref-vol">15</span>:384–5.</span> [<a href="/pubmed/10737993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10737993</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.norby.2004.277">Norby SM, Milliner DS. Outcomes and complications of pregnancy in women with primary hyperoxaluria. <span><span class="ref-journal">Am J Kidney Dis. </span>2004;<span class="ref-vol">43</span>:277–85.</span> [<a href="/pubmed/14750093" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14750093</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.riedel.2011.e26021">Riedel TJ, Johnson LC, Knight J, Hantgan RR, Holmes RP, Lowther WT. Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria. <span><span class="ref-journal">PLoS One. </span>2011;<span class="ref-vol">6</span>:e26021.</span> [<a href="/pmc/articles/PMC3188589/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3188589</span></a>] [<a href="/pubmed/21998747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21998747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.riedel.2012.1544">Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. <span><span class="ref-journal">Biochim Biophys Acta. </span>2012;<span class="ref-vol">1822</span>:1544–52.</span> [<a href="/pmc/articles/PMC3418427/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3418427</span></a>] [<a href="/pubmed/22771891" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22771891</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.rumsby.2001.1697">Rumsby G, Sharma A, Cregeen DP, Solomon LR. Primary hyperoxaluria type 2 without L-glycericaciduria; is the disease under-diagnosed? <span><span class="ref-journal">Nephrol Dial Transplant. </span>2001;<span class="ref-vol">16</span>:1697–9.</span> [<a href="/pubmed/11477177" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11477177</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.schellfeith.2010.221">Schell-Feith EA, Kist-van Holthe J, van der Heijden AJ. Nephrocalcinosis in preterm neonates. <span><span class="ref-journal">Pediatr Nephrol. </span>2010;<span class="ref-vol">25</span>:221–30.</span> [<a href="/pubmed/18797936" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18797936</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.tang.2015.623">Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, Lieske JC. Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. <span><span class="ref-journal">Kidney Int. </span>2015;<span class="ref-vol">87</span>:623–31.</span> [<a href="/pmc/articles/PMC4344931/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4344931</span></a>] [<a href="/pubmed/25229337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25229337</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.von_schnakenburg.1994.27">von Schnakenburg C, Byrd DJ, Latta K, Reusz GS, Graf D, Brodehl J. Determination of oxalate excretion in spot urines of healthy children by ion chromatography. <span><span class="ref-journal">Eur J Clin Chem Clin Biochem. </span>1994;<span class="ref-vol">32</span>:27–9.</span> [<a href="/pubmed/8167190" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8167190</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.watts.1994.593">Watts RWE. Primary hyperoxaluria type 1. <span><span class="ref-journal">QJM. </span>1994;<span class="ref-vol">87</span>:593–600.</span> [<a href="/pubmed/7987654" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7987654</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.williams.2015.69">Williams EL, Bagg EA, Mueller M, Vandrovcova J, Aitman TJ, Rumsby G. Performance evaluation of Sanger sequencing for the diagnosis of primary hyperoxaluria and comparison with targeted next generation sequencing. <span><span class="ref-journal">Mol Genet Genomic Med. </span>2015;<span class="ref-vol">3</span>:69–78.</span> [<a href="/pmc/articles/PMC4299716/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4299716</span></a>] [<a href="/pubmed/25629080" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25629080</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.williams.2012.3191">Williams EL, Bockenhauer D, van't Hoff WG, Johri N, Laing C, Sinha MD, Unwin R. VIljoen A, Rumsby G. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2012;<span class="ref-vol">27</span>:3191–5.</span> [<a href="/pubmed/22391140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22391140</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph3.REF.worcester.2010.954">Worcester EM, Coe FL. Calcium kidney stones. <span><span class="ref-journal">N Engl J Med. </span>2010;<span class="ref-vol">363</span>:954–63.</span> [<a href="/pmc/articles/PMC3192488/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3192488</span></a>] [<a href="/pubmed/20818905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20818905</span></a>]</div></li></ul></div></div><div id="ph3.Chapter_Notes"><h2 id="_ph3_Chapter_Notes_">Chapter Notes</h2><div id="ph3.Author_Notes"><h3>Author Notes</h3><p><a href="http://www.rarekidneystones.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">The Rare Kidney Stone Consortium</a>, funded by the NIDDK and CCATS, is a member of the Rare Disease Clinical Research Network of the National Institutes of Health. The Consortium maintains registries for patients with primary hyperoxaluria, enteric hyperoxaluria, cystinuria, Dent disease, and APRT deficiency. A biobank, protocols for genetic testing, and a number of other protocols are open to enrollment for patients with these diseases.</p></div><div id="ph3.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>24 September 2015 (me) Review posted live</div></li><li class="half_rhythm"><div>13 February 2015 (dsm) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK316514</span><span class="label">PMID: <a href="/pubmed/26401545" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">26401545</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ph2/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/trimethylaminuria/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK316514&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK316514/?report=reader">PubReader</a></li><li><a href="/books/NBK316514/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK316514" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK316514" style="display:none" title="Cite this Page"><div class="bk_tt">Milliner DS, Harris PC, Lieske JC. Primary Hyperoxaluria Type 3. 2015 Sep 24. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK316514/pdf/Bookshelf_NBK316514.pdf">PDF version of this page</a> (371K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ph3.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ph3.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ph3.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ph3.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ph3.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ph3.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ph3.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ph3.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ph3.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ph3.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ph3.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=112817[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HOGA1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4121452" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4121452" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4121452" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4121452" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301460" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Primary Hyperoxaluria Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Primary Hyperoxaluria Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Milliner DS, Harris PC, Cogal AG, Lieske JC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301742" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Primary Hyperoxaluria Type 2</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Primary Hyperoxaluria Type 2<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Rumsby G, Hulton SA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25905296" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nephrolithiasis</a><span class="source">[Endotext. 2000]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nephrolithiasis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Favus M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Endotext. 2000</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26150027" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.</a><span class="source">[Arch Ital Urol Androl. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Prezioso D, Strazzullo P, Lotti T, Bianchi G, Borghi L, Caione P, Carini M, Caudarella R, Ferraro M, Gambaro G, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Arch Ital Urol Androl. 2015 Jul 7; 87(2):105-20. Epub 2015 Jul 7.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12649986" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].</a><span class="source">[Ther Umsch. 2003]</span><div class="brieflinkpop offscreen_noflow">[Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hess B. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ther Umsch. 2003 Feb; 60(2):79-87. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=26401545" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=26401545" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e042a45dde0891169ac5348">Primary Hyperoxaluria Type 3 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Primary Hyperoxaluria Type 3 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:34:29-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8DEB54E0420AC100000000044001BD&amp;ncbi_session=CE8DEB54E042A451_1088SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK316514%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK316514&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK316514/&amp;ncbi_pagename=Primary Hyperoxaluria Type 3 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8DEB54E042A451_1088SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>